Literature DB >> 24480972

Validation of nomograms predicting lymph node involvement in patients with prostate cancer undergoing extended pelvic lymph node dissection.

Alexander I Hinev1, Deyan Anakievski, Nikolay H Kolev, Vesselin I Hadjiev.   

Abstract

Our aim was to validate Briganti's nomograms predicting the probability of lymph node involvement (LNI) in prostate cancer (PCa). Clinicopathological data of 256 PCa patients who underwent extended pelvic lymph node dissection (ePLND) and radical prostatectomy (RP) were obtained from two Bulgarian institutions. Predicted probabilities of LNI were assessed using Briganti's nomograms based on ePLND. In addition to the established basic LNI predictors, Briganti's nomograms included the number of lymph nodes removed (version 2006) and the number and percentage of positive biopsy cores (versions 2007 and 2012). The accuracy of these nomograms was compared with the updated Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram (version 2011). Receiver-operating characteristics analysis was done to assess the discriminative ability of each of the nomograms applied. All of Briganti's nomograms showed a higher predictive accuracy as compared with the updated MSKCC nomogram. The respective AUC values were calculated as 0.847, 0.837, 0.858 and 0.875 for the four Briganti nomograms, and 0.770 for the updated MSKCC nomogram, respectively. Despite the potential for heterogeneity in patient selection and management, all predictions demonstrated high concordance with actual observations. Compared with other similar prognostic tools the updated Briganti nomogram (version 2012) showed the highest predictive accuracy and should therefore be preferred. 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 24480972     DOI: 10.1159/000354323

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Histological Validation of 11Carbon-Acetate Positron Emission Tomography/Computerized Tomography in Detecting Lymph Node Metastases in Prostate Cancer.

Authors:  Nieroshan Rajarubendra; Fabio Almeida; Zarko Manojlovic; Chisato Ohe; Nariman Ahmadi; Giovanni Cacciamani; Michael Qiu; Andre Abreu; Jie Cai; Gus Miranda; Mariana C Stern; John Carpten; Peter Kuhn; Mahul B Amin; Parkash S Gill; Manju Aron; Inderbir S Gill
Journal:  J Urol       Date:  2019-02       Impact factor: 7.600

2.  Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.

Authors:  Masahiro Yashi; Akinori Nukui; Yuumi Tokura; Kohei Takei; Issei Suzuki; Kazumasa Sakamoto; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Hideyuki Abe; Yoshitatsu Fukabori; Yoshimasa Nakazato; Yasushi Kaji; Takao Kamai
Journal:  BMC Urol       Date:  2017-06-23       Impact factor: 2.264

Review 3.  A narrative review of pelvic lymph node dissection in prostate cancer.

Authors:  Douglas C Cheung; Neil Fleshner; Shomik Sengupta; Dixon Woon
Journal:  Transl Androl Urol       Date:  2020-12

4.  E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy.

Authors:  Piotr Zapała; Łukasz Fus; Zbigniew Lewandowski; Karolina Garbas; Łukasz Zapała; Barbara Górnicka; Piotr Radziszewski
Journal:  J Clin Med       Date:  2021-11-27       Impact factor: 4.241

5.  Incidence Trends and Survival Prediction of Malignant Skin Cancer: A SEER-Based Study.

Authors:  Sirong Zhu; Chao Sun; Longjiang Zhang; Xiaoan Du; Xiaodong Tan; Shuzhen Peng
Journal:  Int J Gen Med       Date:  2022-03-15

6.  Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.

Authors:  Zilvinas Venclovas; Tim Muilwijk; Aivaras J Matjosaitis; Mindaugas Jievaltas; Steven Joniau; Daimantas Milonas
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.